Tag:
Eli Lilly
Latest Headlines
Latest Headlines
Mined doctor-patient data gives drugmakers insight for targeted marketing
The recent layoffs of hundreds of drug sales reps mean there are fewer people in the field calling on doctors to see what they are prescribing. But they don't have to--drugmakers have found new tools that actually can tell them more about doctors' prescribing patterns than the physicians even know themselves.
Eli Lilly jettisons cancer contender after another Phase III failure
The Indianapolis-based drug giant has slammed the brakes on development of enzastaurin, which failed to meet the main goal for boosting disease-free survival in a Phase III study of patients with diffuse large B-cell lymphoma.
Lilly CEO set for surgery on dilated aorta; CFO steps up temporarily
Eli Lilly Chairman and CEO John Lechleiter is scheduled for surgery for a dilated aorta on Monday and will hand the CEO reins over to CFO Derica Rice as he recovers. If all goes well, he'll be back on the job later this summer, the company said.
UPDATED: Lilly tells 1,624 their sales jobs are gone or changed
Salesforce cuts are coming down at Eli Lilly, and 40% of its U.S. sales force will be out. According to the company, the drugmaker sent a state Warn Notice to 1,624 sales positions, of which about 1,000 will be let go.
Eli Lilly, Insulet to develop Humulin-specific OmniPod
Insulet, creator of the OmniPod tubeless insulin pump, joined forces with Eli Lilly this week to develop a new version of the device designed to deliver Lilly's Humulin R U-500 insulin.
Eli Lilly slugs it out with J&J on Alzheimer's drug patent claim
With a new late-stage study being prepped for the Alzheimer's drug solanezumab, Eli Lilly found itself in a London courtroom this week defending itself against a patent claim by Johnson & Johnson, one of its chief rivals in the risky game of Alzheimer's drug development.
Lilly cost-cutting and price hikes pay off with Q1 earnings beat
The moral of Eli Lilly's first-quarter performance is this: Raise prices and cut costs.
Eli Lilly targets journos on Twitter and Facebook as pharma coverage goes social
In recent weeks, Eli Lilly has been flexing its social media muscles in an effort reach out to journalists on the popular platforms of Facebook and Twitter.
Safety watchdog flags GLP-1 drugs for pancreatitis reports to FDA
A safety watchdog group has analyzed the FDA's adverse event data on the entire GLP-1 class of diabetes drugs, finding more reports of pancreatitis and pancreatic cancer for these drugs compared with older treatments.
Siemens selling Alzheimer's Dx agents to Lilly
Eli Lilly plans to buy two of Seimens Healthcare Alzheimer's imaging agents, used in PET scans, all part of the drugmaker's shifting approach to treating the disease.
